Y-mabs therapeutics executive trades shares worth over $720k By Investing.com

In a recent move, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) executive Bo Kruse, who serves as the company’s EVP, CFO, Secretary & Treasurer, engaged in significant trading activity involving the company’s stock. The transactions, which took place on May 30 and 31, included both acquisitions and disposals of shares.

According to the filings, Kruse sold a total of 60,000 shares of common stock over the two days, with the sales generating over $720,000. The shares were sold at prices ranging from $11.85 to $12.22, with the weighted average prices reported at $12.03 and $12.07 for each respective day.

In addition to the sales, Kruse also exercised options to acquire 60,000 shares of Y-mAbs Therapeutics common stock at a price of $2.00 per share, totaling $120,000. These options were already vested, as noted in the footnotes of the filing.

Following these transactions, Kruse’s ownership in the company stands at 210,877 shares of common stock. The detailed trades reveal the dynamic nature of insider activity, showcasing an executive’s confidence in both realizing gains and investing in the future of the company.

Investors often monitor such insider transactions as they can provide insights into the company’s financial health and the executive’s outlook on the company’s prospects. For Y-mAbs Therapeutics, these recent trades by a top executive may be a point of interest for current and potential shareholders alike.

InvestingPro Insights

As Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) sees significant insider trading activity, it’s vital for investors to consider the company’s financial metrics and market performance for a comprehensive understanding. According to InvestingPro data, Y-mAbs Therapeutics holds a market capitalization of $530.98 million, with a notable gross profit margin of 86.41% for the last twelve months as of Q1 2024. This impressive margin reflects the company’s ability to manage its costs effectively relative to its revenue.

Despite the company’s strong gross profit margins, the P/E ratio stands at -24.51, indicating that investors are paying a premium for non-existent earnings over the last twelve months. Additionally, the stock has experienced a significant price uptick of 96.43% over the last six months, suggesting a positive trend in investor sentiment. This is further supported by a year-to-date price total return of 77.42%, which could be a reaction to the company’s financial performance or other market factors.

InvestingPro Tips highlight that Y-mAbs Therapeutics holds more cash than debt on its balance sheet, which is a positive sign of financial stability. Furthermore, the company’s liquid assets exceed its short-term obligations, ensuring that it can meet its liabilities in the near term. For investors seeking more in-depth analysis, InvestingPro offers additional tips on Y-mAbs Therapeutics, which can be accessed at https://www.investing.com/pro/YMAB. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription and discover 8 more InvestingPro Tips that could help in making informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.